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Abstract
Protein homeostasis, or proteostasis, is the process of maintaining the conformational and functional
integrity of the proteome. The failure of proteostasis can result in the accumulation of non-native proteins
leading to their aggregation and deposition in cells and in tissues. The amyloid fibrillar aggregation of the
protein α-synuclein into Lewy bodies and Lewy neuritis is associated with neurodegenerative diseases
classified as α-synucleinopathies, which include Parkinson's disease and dementia with Lewy bodies. The
small heat-shock proteins (sHsps) are molecular chaperones that are one of the cell's first lines of
defence against protein aggregation. They act to stabilise partially folded protein intermediates, in an
ATP-independent manner, to maintain cellular proteostasis under stress conditions. Thus, the sHsps
appear ideally suited to protect against α-synuclein aggregation, yet these fail to do so in the context of
the α-synucleinopathies. This review discusses how sHsps interact with α-synuclein to prevent its
aggregation and, in doing so, highlights the multi-faceted nature of the mechanisms used by sHsps to
prevent the fibrillar aggregation of proteins. It also examines what factors may contribute to α-synuclein
escaping the sHsp chaperones in the context of the α-synucleinopathies.
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Abstract:
Protein homeostasis, or proteostasis, is the process of maintaining the conformational and functional
integrity of the proteome. The failure of proteostasis can result in the accumulation of non-native
proteins leading to their aggregation and deposition in cells and in tissues. The amyloid fibrillar
5

aggregation of the protein α-synuclein into Lewy bodies and Lewy neuritis is associated with
neurodegenerative diseases classified as α-synucleinopathies, which include Parkinson’s disease
and dementia with Lewy bodies. The small heat-shock proteins (sHsps) are molecular chaperones
that are one of the cell’s first lines of defence against protein aggregation. They act to stabilise
partially folded protein intermediates, in an ATP-independent manner, to maintain cellular
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proteostasis under stress conditions. Thus, the sHsps appear ideally suited to protect against αsynuclein aggregation, yet these fail to do so in the context of the α-synucleinopathies. This review
discusses how sHsps interact with α-synuclein to prevent its aggregation and, in doing so,
highlights the multi-faceted nature of the mechanisms used by sHsps to prevent the fibrillar
aggregation of proteins. It also examines what factors may contribute to α-synuclein escaping the
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sHsp chaperones in the context of the α-synucleinopathies.
Keywords:
α-synuclein, αB-crystallin, amyloid, protein aggregation, proteostasis, Parkinson’s disease
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Highlights (3-5 bullet points):


α-synucleinopathies are diseases associated with α-synuclein aggregation.



Small heat-shock proteins are molecular chaperones that prevent protein aggregation.



Small heat-shock proteins could be therapeutic targets for the α-synucleinopathies.
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Abbreviations
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αA-c, αA-crystallin; αB-c, αB-crystallin; α-syn, α-synuclein; AFM, atomic force microscopy;
ALS, amyotrophic lateral sclerosis; DA, dopamine; EGFP, enhanced green fluorescent protein;
Hsp, heat-shock protein; PD, Parkinson’s disease; ROS, reactive oxygen species; sHsp, small heatshock protein; TEM, transmission electron microscopy.
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Introduction

Protein homeostasis (proteostasis) is the maintenance of proteins at appropriate levels and in the
correct (functional) conformation [1]. Proteostasis involves a complex network of integrated
systems, including molecular chaperone proteins, which ensures the conformational (and hence
functional) integrity of synthesised proteins and the degradation of proteins which are no longer
functional. When proteostasis mechanisms falter, proteins can misfold, aggregate and accumulate,
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often resulting in disease [2]. One example of this is the α-synucleinopathies, a group of
neurodegenerative diseases that include Parkinson’s disease (PD), multiple system atrophy and
dementia with Lewy bodies [3], in which the protein α-synuclein (α-syn) aggregates into insoluble
amyloid fibrils and forms deposits (termed Lewy bodies and Lewy neurites) inside cells. While the
aetiology of the α-synucleinopathies is multi-faceted, this review will focus specifically on the links
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of these diseases with the fibrillar aggregation of α-syn (for a more comprehensive review of the
pathology and genetics of the α-synucleinopathies, see [4-8]).
Heat-shock proteins (Hsps) are a broad family of molecular chaperones that play important roles in
proteostasis. They function under normal physiological conditions and when cells are under stress,
e.g. when they are exposed to elevated temperatures or reactive oxygen species (ROS) [9]. One of
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the most up-regulated classes of Hsps induced by stress is the small heat-shock proteins (sHsps) and
they have been implicated as important components of the cellular response to the onset of many
protein aggregation disorders, including the α-synucleinopathies.
The sHsps act as the cell’s first line of defence against protein aggregation. Their ability to prevent
protein aggregation in vitro has been well characterised using a variety of pathogenic and non-
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pathogenic proteins [10-13], including α-syn [11, 14, 15]. Yet since the α-synucleinopathies occur,
it is evident that there are some circumstances whereby sHsps (and other classes of molecular
chaperones) fail to prevent the aggregation of α-syn in vivo. This review outlines the role of sHsps
in cellular proteostasis, with a particular focus on αB-crystallin (HSPB5, αB-c) and Hsp27

3

(HSPB1), as these have been the most studied sHsps, including in the context of the α60

synucleinopathies (for recent reviews that focus on the association and impact of other major
chaperone classes, e.g. Hsp70 and Hsp90, on the α-synucleinopathies see [16-19]). In doing so, this
review provides insight into how these sHsps normally interact with α-syn to prevent its toxic
fibrillar aggregation, and what factors may account for the chaperone activity of sHsps being
ineffective and/or overwhelmed in the α-synucleinopathies.
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2.

Proteostasis

Proteostasis operates both inside and outside the cell (for recent comprehensive reviews see [20,
21]) and is dependent on numerous integrated pathways that control the lifecycle and fate of a
protein (Figure 1). These pathways include those involved in gene transcription, mRNA translation
and protein synthesis on the ribosome, through to protein trafficking and compartmentalisation in
70

cellular organelles, and finally to protein degradation by the proteasome [22]. As such, the
macromolecular elements comprising the cellular proteostasis network include transcription factors,
RNA processing and translocation factors, folding enzymes, trafficking components, molecular
chaperones and degradation components. The capacity to maintain proteostasis varies between cell
types [23], and is thought to be reflective of the composition and concentration of components of
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the network that arise as a result of differences during cellular differentiation and development [24].
Whilst this capacity is finite at any point in time, it can be spatially and temporally altered through
varying the amount and/or activity of individual components. Thus, an appropriate analogy for
proteostasis is a see-saw; there is an intricate balance required in the use of energy and resources to
maintain the functional integrity of the proteome and thus avoid protein aggregation and disease.
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2.1 Molecular chaperones
The biological function of (most globular) proteins is inextricably linked to them obtaining the
correct (native) fold [25]. However, many proteins are intrinsically disordered and do not fold;
instead they remain unfolded with some acquiring structure once they bind to other proteins or

4

membranes [26-28]. Unfolding is important in the life cycle of many proteins; it is required in
85

various biological processes including protein trafficking, secretion and translocation across
membranes, as well as regulation of the cell cycle [29]. In all cases, attaining the correct native
state, whether folded or disordered, is essential for protein function and often relies on the presence
of molecular chaperones. Molecular chaperones
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Figure 1: Cellular proteostasis mechanisms. In the endoplasmic reticulum (ER), molecular chaperones assist newly
synthesised protein intermediates to fold into their native conformation for transport into the cytosol. Persistent or
misfolded protein intermediates can be proteolytically degraded within the ER or transported to the cytosol [30]. Once
in the cytosol, protein intermediates are recognised by molecular chaperones and targeted for refolding or degradation
via lysosomal or proteasomal pathways [31]. When these mechanisms fail to clear protein intermediates, insoluble
aggregates can accumulate within the ER or cytosol as aggresomes. Adapted from [22].

protect and stabilise non-native regions of proteins, or assist in proteins acquiring their native state,
without contributing conformational information or forming part of the final native structure [32,
33]. Chaperones achieve this by interacting with (and stabilizing) partially folded and unfolded
100

protein intermediates in order to prevent improper associations that could otherwise lead to
misfolding and aggregation [34]. In addition, chaperones can also facilitate the folding of multidomain proteins, through transient sequestration of the folding intermediates [24].

5

Due to their role in assisting proteins to acquire and maintain their native conformation, molecular
chaperones are key components of the proteostasis network. They participate in protein folding,
105

complex assembly, protein trafficking, protein stabilisation and protein degradation. As their name
implies, Hsps are molecular chaperones that are most commonly expressed as part of the cellular
response to stress, although some members are constitutively expressed and play important roles
under non-stress conditions [35]. The Hsps have been classified into groups based on the mass of
their monomeric subunits. They include Hsp100, Hsp90, Hsp70, Hsp60 and the sHsps [36].
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Chaperones can also be generally classified as having either a ‘foldase’ or ‘holdase’ type action. For
example, Hsp70 and Hsp60 are classified as ‘foldase’ type chaperones as they actively facilitate the
folding of protein intermediates to their native folded state. In doing so, they often act in tandem,
with Hsp70 acting first on the polypeptide chain upon its exit from the ribosome. Their mechanism
of action is dependent on ATP hydrolysis, which results in cycles of high- to low-affinity target
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protein binding, which promotes folding of the target protein [37, 38]. Foldase chaperones also
encompass the so-called ‘unfoldase’ action attributed to some chaperones, including Hsp70, in
which ATP hydrolysis is used to unfold or disaggregate misfolded or aggregated proteins to provide
folding-competent intermediates [39, 40]. In contrast, so-called ‘holdase’ chaperones, which include
the sHsps, interact with the partially folded intermediate states of proteins to stabilise them and
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prevent their mutual association. The mechanism of action of holdase chaperones is ATPindependent since they do not have an active role in folding proteins and their association with
target proteins is driven primarily through hydrophobic interactions. However, the ability of
holdases to function in the ATP-depleted environment that occurs in the cell when it is under stress
ensures their function is not compromised at the time cell viability is threatened. When energy
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levels permit, holdase chaperones can deliver target proteins to foldases for refolding, or to the
cellular protein degradation systems such as the proteasome [37, 38, 41].
2.1.1

The role of molecular chaperones in protein degradation

6

When a protein can no longer maintain its correct conformation, the cell utilises degradation
pathways such as the ubiquitin-proteasome machinery and autophagic-lysosomal trafficking
130

systems to remove it. Misfolded proteins are recognised by the ubiquitin-proteasome system, which
labels and degrades them through a highly regulated pathway. Using a series of ubiquitin ligase
enzymes, ubiquitin polypeptide chains are covalently linked to misfolded proteins, marking them as
substrates for selective degradation within the proteasome [42, 43]. Lysosomal mechanisms, such as
macroautophagy and microautophagy, are less selective; membrane-bound vesicles capture a
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selection of the cytosol, which is then targeted for degradation. By contrast, chaperone-mediated
autophagy provides a level of targeted degradation as it relies on the recognition of a target motif in
cytosolic proteins by specific chaperones, which then deliver the proteins to the membrane of the
lysosome for internalisation and degradation [44]. The sHsps may play a role in all of these
degradation pathways; for instance, αB-c (HSPB5) stimulates ubiquitination of insoluble proteins
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which marks them for ubiquitin-dependent degradation [45], Hsp22 (HspB8), in cooperation with
Bag3, promotes degradation of mutant Huntington protein through induction of macroautophagy
[46] and Hsp27 (HSPB1) targets misfolded cystic fibrosis transmembrane conductance regulator
proteins for degradation in the proteasome [47]. Whether these activities are specific to individual
sHsps or represent more generic traits of sHsp family members is yet to be determined, however it
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is clear from this work that as a chaperone class, sHsps function not only to maintain proteins in
their biologically active conformation but can also facilitate their degradation when misfolded [48].
2.2 When proteostasis fails
A number of factors can influence the ability of a cell, tissue or organism to maintain proteostasis.
Changes in cellular ATP levels, amino acid pools, metabolites, lipid homeostasis and ion balance
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can all disrupt the protein folding and degradation capabilities of the cell [24]. Signalling pathways
can be exploited to control transcriptional, translational and post-translational mechanisms in the
cell in order to regulate protein synthesis, folding, trafficking and degradation [24]. However,
disruption of any element within this integrated network can result in proteostasis dysfunction.
7

Aberrant protein folding and protein aggregation are now recognised as key factors in many
155

diseases, collectively termed protein misfolding or conformational diseases [49]. These diseases,
which include type II diabetes, cataract and neurological disorders such as Alzheimer’s disease and
PD [50], are associated with the aggregation and precipitation of misfolded protein into either
amorphous or fibrillar aggregates. Their prevalence, and the prediction that this will increase
dramatically over the next few decades as a consequence of the ageing population in many
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countries [51], underlies the importance of understanding the network of pathways that maintain
proteostasis.

3.

Parkinson’s disease is an aggregation disorder

PD is the second most prevalent neurological disorder, with its world-wide incidence projected to
165

reach at least 8.7 million individuals over 50 years of age by 2030 [51-53]. PD is characterised by
motor manifestations including tremor, rigidity, bradykinesia and postural instability, which can
also be accompanied by non-motor symptoms such as sleep impairment, neuropsychiatric disorders
and olfactory deficits [54, 55]. All of these symptoms are linked to a gradual reduction in dopamine
content associated with the progressive loss of dopaminergic neurons in the substantia nigra pars
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compacta, a region located in the midbrain.
The histological hallmark of PD is the presence of protein inclusions, known as Lewy bodies or
Lewy neurites, localised to the cell body or cell processes respectively [56]. These distinctive
spherical protein inclusions are found in the cytoplasm of nigral neurons and are characterised by a
dense protein core surrounded by a halo of fibrils and auxiliary proteins [57]. The principal protein
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contained within these inclusions is α-syn [58]. The α-syn-rich proteinaceous deposits are not only
found in PD but are also detected in other neurological disorders including dementia with Lewy
bodies, some forms of Alzheimer’s disease and multiple system atrophy [59-61].

8

Since α-syn is expressed in cell types other than neurons, often at higher levels (e.g. red blood cells
[62, 63]), the question arises: why are neurons so susceptible to forming α-syn inclusions? Neurons
180

are thought to be particularly vulnerable to these protein accumulations as they are post-mitotic and
therefore unable to dilute potentially toxic species through cell division [64]. Moreover, expression
of some molecular chaperones, including the sHsps, appears to be lower in dopaminergic neurons
compared to other cell types which may compromise their ability to prevent protein aggregation
[23].
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3.1 α-Synuclein in Parkinson’s disease
α-Synuclein, a 140 amino acid protein, was initially identified as a neuron-specific protein localised
within the nucleus and presynaptic terminals [65]. From a functional perspective, there is still no
definitive evidence for the role α-syn plays in cells. It has been implicated in modulating synaptic
activity through membrane processes, including neurotransmitter release, trafficking and biogenesis
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[66, 67]. In addition to the full-length form of the protein, there are two shorter isoforms which are
126 and 112 amino acids in length and result from in-frame deletions of exon 3 and 5 respectively
[68, 69]. However the full length isoform is by far the most abundant in the brain [70]. Truncated
versions, derived from proteolytic cleavage, have been identified as significant components of
Lewy body inclusions [60, 70, 71]. Truncation fragments of α-syn also have a higher aggregation
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propensity than the full length form, both in vitro and in vivo [72-75].
As well as the association of α-syn with Lewy body pathology, there is a strong genetic association
of α-syn with PD [76] which has further piqued interest into the role of this protein in disease. PD
may be either early onset (before) or late onset (after 40 years of age). Although most commonly
presenting as a late onset, sporadic disease of unknown aetiology, a familial form with an autosomal
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dominant pattern of inheritance among early onset patients was initially identified in two small
kindred [77, 78]. This led to the identification of three missense mutations in the α-syn gene which
correlate to early-onset and aggressive PD: A53T, A30P and E46K [76, 79, 80]. Multiplication of

9

the α-syn gene has also been associated with the development of α-syn inclusions [60, 71]. Gene
copy number is strongly correlated with the age of disease onset; duplication results in an average
205

age of onset of 48.4 years, while triplication results in an average age of onset of 33.4 years [81].
3.1.1 α-Synuclein aggregation
Due to the presence of large amounts of aggregated α-syn in Lewy bodies and Lewy neurites, and
the correlation between α-syn genetic abnormalities and early onset PD, the mechanism and kinetics
by which α-syn aggregates to form amyloid fibrils in vitro have been examined in detail (Figure 2).
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It has been generally accepted that α-syn exists as an unstructured monomeric protein in its native
state in solution. However, when the N-terminus of monomeric α-syn interacts with lipids it attains
an α-helical structure and recent evidence has suggested it may form a tetramer in some cell types
[82-86]. Within inclusions, α-syn is assembled into highly-ordered, β-sheet rich amyloid fibrils.
Similarly, under conditions of physiological pH and temperature in vitro, purified α-syn assembles
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into fibrils resembling those found in diseased brains [87-89]. Amyloid fibril formation occurs via a
nucleation-dependent mechanism in which the formation of oligomeric nuclei is the rate limiting
step, which is followed by rapid elongation and assembly into mature fibrils [90-92]. All three αsyn mutations associated with PD have been found to influence the early stages of aggregation,
either nuclei formation or fibril growth, when their aggregation propensities have been assessed in
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vitro [93]. Each α-syn mutant exhibits distinct fibrillation kinetics and/or aggregate morphologies:
A53T and E46K α-syn form fibrils more rapidly than the wild-type (WT) protein, and A30P α-syn
forms mature fibrils more slowly, although smaller oligomeric species are formed more rapidly by
this mutant [15, 94, 95]. The difference in fibrillation kinetics is generally attributed to variations in
the rate of nucleation, as opposed to the rate of elongation [96, 97]. As with gene multiplication, the
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aggregation propensity of each α-syn variant correlates well with disease onset and the severity of
familial PD, with the A53T variant aggregating the fastest and being associated with the earliest and
most aggressive disease phenotype [98].

10
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Figure 2: Amyloid fibrillar aggregation of α-syn. Unfolded α-syn exists as a monomer that can interact with lipids, to
form an α-helical structure [85]. There is some evidence that a tetrameric α-helical form of α-syn also exists in cells
[84] and monomeric unfolded forms of α-syn may be in equilibrium with this tetramer. Unfolded α-syn aggregates
through a nucleation-dependent mechanism, in which aggregation-prone α-syn monomers associate to form soluble
prefibrillar oligomeric nuclei. This is followed by the elongation of these nuclei into mature amyloid fibrils. Fibrillar
aggregates may then be sequestered into Lewy body or Lewy neurites. Alternatively, fragmentation of mature fibrils
can generate additional oligomeric nuclei which seed secondary aggregation events.

In addition to the inherent aggregation propensity of α-syn, a number of factors have been shown to
influence the rate at which the protein forms fibrils. For example, aggregation is promoted by the
presence of metals, pesticides, lipids, membranes, and under conditions of low pH or molecular
240

crowding [99-101]. In general, these factors increase the concentration of the prefibrillar
intermediates crucial for the formation of nuclei during the rate-limiting step [57, 99-101].
Conversely, aggregation is hindered by the presence of β- and γ-synucleins [102, 103], as well as
molecular chaperones such as sHsps [15, 104]. Changes in the rate at which aggregation occurs
(e.g. through the influence of the above mentioned factors), may therefore contribute to the failure
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of proteostasis elements to prevent α-syn aggregation in a disease context.
3.1.2 α-Synuclein pathogenicity
Although the exact physiological function of α-syn is yet to be defined, based on knowledge of its
broad physiological role of modulating synaptic activity, some features of PD may be ascribed to
toxicity associated with loss of function encountered when α-syn in the cell is sequestered and
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deposited following aggregation. The reduced availability of α-syn would impact on its ability to
interact with cellular membranes [105]. Failure of α-syn to complete its physiological role within

11

the cell could potentially cause neuronal damage, particularly in the synaptic terminal [106].
However, it is considered unlikely that this is the primary pathological effect of α-syn aggregation
since α-syn knockout mice do not display any overt neuropathological or behavioural phenotypes,
255

in contrast to mice that overexpress α-syn [107, 108]. Instead, it is now generally accepted that the
accumulation of α-syn into Lewy bodies and Lewy neurites leads to disease due to a toxic gain-offunction inherent in the protein when it exceeds a threshold concentration and adopts a fibrillar-type
conformation [106]. The aggregation of α-syn, exacerbated by a decrease in the ability of the cell to
dispose of damaged proteins, results in the accumulation of non-functional (potentially toxic) α-syn
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species, which may interfere with normal metabolic processes.

3.1.3

The debate surrounding the identity of the cytotoxic α-synuclein species

For some time, the toxic α-syn species responsible for neurodegeneration has been hotly debated.
Initially, cytoplasmic inclusions were thought to be a characteristic feature of dead or dying
265

neurons, with the deposition of mature amyloid fibrils into Lewy bodies identified as the neurotoxic
event. This was primarily based on findings suggesting that inclusions may suppress organelle
function, interfere with axonal transport, or induce energy failure via hyperubiquitination [109,
110]. However, Lewy bodies are commonly found in living neurons, and are also present in up to
15% of healthy, aged individuals [111, 112].
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In cell-based models and in vivo, neurotoxicity correlates best with the appearance of soluble α-syn
oligomers as opposed to inclusions [113]. Toxicity is usually observed in the absence of mature αsyn fibrils or detectable deposition into inclusions in cell models [113, 114]. Moreover, surviving
dopaminergic neurons demonstrate equivalent viability irrespective of the presence or absence of
Lewy bodies [115]. Furthermore, transgenic mice exhibit neurodegeneration outside the substantia
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nigra in the absence of fibrillary inclusions, and α-syn fibril-containing inclusions in Drosophila are
observed in the absence of neurodegeneration [116-118].

12

A recent study utilised a rat lentivirus system to examine the cellular toxicity of E35K and E37K αsyn, which were specifically designed to form small oligomers, compared to an α-syn variant
encompassing residues 30-110, which forms fibrils [119]. Following injection into the substantia
280

nigra, cell loss was assessed based on a reduction in tyrosine hydroxylase-positive neurons in this
region. Higher toxicity was observed in dopaminergic neurons of animals exposed to oligomerforming variants of α-syn compared to that which formed fibrils [119]. Finally, dopamine and its
metabolites inhibit the conversion of protofibrils to mature amyloid both in vitro and in vivo [120122], providing a potential rationalisation for the vulnerability of dopaminergic neurons since they
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would therefore promote protofibril formation. Alternatively, dopamine may act as a source of ROS
in a process potentiated by α-syn, thereby promoting apoptosis [114].
In light of this evidence, the predominant consensus is now that soluble prefibrillar oligomeric
species of α-syn are the most toxic entity, and fibrils are the less toxic end-product of the
aggregation process [123, 124]. Yet, mature fibrils can be a source of cytotoxic oligomeric species
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due to their fragmentation [125]. Thus, it has been proposed that the formation of protein inclusions
may represent an additional protective mechanism employed by the cell [61, 123, 126]. The
formation of inclusion bodies within cells may therefore represent a protection strategy used by the
cell to sequester toxic oligomeric forms that may arise due to fibril fragmentation. In this way,
potentially toxic species can be isolated in specific compartments in the cell to protect it from their
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harmful effects [127].
The generic toxicity of prefibrillar (i.e. small soluble oligomeric) species is also evident in nondisease-associated proteins capable of forming amyloid. For example, using two unrelated and nondisease-associated protein domains, the SH3 domain from bovine phosphatidyl-inositol-3’-kinase
and the amino terminal of HypF from E. coli, Bucciantini and colleagues [128] demonstrated that
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oligomeric forms of these proteins generated during the early stages of aggregation were inherently
cytotoxic when added to cells in culture. As well, early prefibrillar aggregates of apomyoglobin are
toxic to cultured fibroblasts via their ability to alter membrane permeability [129]. Finally, soluble
13

amyloidogenic oligomers of equine lysozyme are toxic to both primary and cultured neuronal cells;
cytotoxicity is correlated with the size of the oligomers within the sample with larger species being
305

less cytotoxic [130]. Thus, it is concluded that prefibrillar aggregates are the most toxic entity
formed during amyloid fibril formation.
The toxicity of aggregates formed from a variety of pathogenic and non-pathogenic proteins
correlates with the level of exposed hydrophobicity at the aggregate surface [131]. Initially, there is
an abundance of soluble oligomeric aggregates with a high surface-to-volume ratio and a high
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degree of exposed hydrophobicity [132]. As the aggregate increases in size over time, there is a
decrease in the surface-to-volume ratio and amount of exposed hydrophobicity [131-133]. The
higher proportion of hydrophobic residues exposed on the smaller oligomeric species enables them
to participate in inappropriate interactions that can ultimately lead to cell death [49]. It is important
to note, however, that although this mechanism appears generally applicable to pathogenic and non-
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pathogenic proteins alike, ultimately the amino acid sequence defines the kinetics by which a
protein aggregates and the specific properties of any aggregate formed. Thus, the specific toxicity of
a protein is influenced by its relative ability to form oligomers, the rate these oligomers are then
converted to mature fibrils and the amount of hydrophobicity exposed throughout this process
[131].
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The relative hydrophobicity of prefibrillar aggregates appears to endow them with a large potential
to cause cellular damage. Many mechanisms have been proposed for α-syn toxicity (summarised in
Figure 3). When considering the mechanism of toxicity of these species, it is important to also take
into account their physical properties. For example, α-syn is capable of lipid-binding [134, 135] and
the oligomers formed from α-syn can be small, flexible spheroids, characteristics which favour their
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association with membranes and pore formation [136]. Pore formation may occur on any of the
cellular membranes, both inter- and intra-cellular, providing several targets for α-syn mediated
toxicity [137]. For instance, pore formation within the plasma membrane may allow the abnormal
flow of ions causing cellular dysfunction and leading to apoptosis [134, 138]. This is indirectly
14

supported by work showing that cells expressing α-syn have increased cation permeability [139].
330

Through interaction with lysosomal membranes, α-syn aggregates may inhibit chaperone-mediated
autophagy, leading to an accumulation of substrates and proteasome inhibition [140]. Alternatively,
prefibrillar oligomers can impair axonal transport via hyperphosphorylation of Tau, a protein
normally responsible for stabilising and regulating the microtubule assembly and interacting with
membranous cargo [141]. By disrupting transport from the endoplasmic reticulum (ER) to Golgi, α-
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syn can cause ER stress and Golgi fragmentation [113, 140]. Energy production can also be
impaired due to effects of oligomeric α-syn on mitochondria [142]. In addition, α-syn is implicated
in reducing dopamine release and its subsequent reuptake in the synaptic terminal [143]. The active
secretion or passive release (following death) of aggregated forms of α-syn can also result in cell-to-
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Figure 3: A schematic model for the potential mechanisms by which α-syn aggregation is toxic to neuronal cells.
Aggregation-prone monomeric α-syn associates to form soluble oligomeric nuclei leading to the formation of mature
fibrils. (1) Inclusion body formation: Fibrillar α-syn is sequestered into protein inclusions, which also contain various
other cellular proteins, including sHsps, potentially depleting the cell of these essential components (2) Initiation of the
heat-shock response: An accumulation of toxic α-syn species within the cell activates the heat-shock response
pathway, initiating changes in transcription of stress response genes. (3) Blocking protein trafficking from the ER to
Golgi: Aggregation of toxic forms of α-syn in the cell can block protein transport from the ER to Golgi, inducing Golgi
fragmentation. (4) Oxidative stress: Aggregation of α-syn induces dopamine (DA)-dependent ROS production,
resulting in oxidative stress. (5) Defects in axonal transport: Aggregated α-syn induces hyperphosphorylation of tau
in the axon, which causes defects in axonal transport through restricting the ability of tau to modulate microtubule
assembly. This impairs essential cellular transport as well as resulting in the accumulation of aggregated material in the
cell body. (6) Altered synaptic terminal excitability and protein expression: The presence of aggregated α-syn in the
synaptic compartment alters the distribution of synaptic terminal proteins, diminishing synaptic vesicle release and
leading to changes in synaptic terminal protein expression and excitability. (7) Impaired autophagy: Binding of α-syn
to lysosomal membranes impairs chaperone-mediated autophagic function, resulting in substrate accumulation and
proteasomal impairment in the cell body. (8) Release of toxic α-syn species into extracellular space: Aggregated αsyn may be actively secreted (e.g. via exosomes) or passively released by dying neurons and be subsequently taken up
by neighbouring neurons, resulting in seeded aggregation and altered synaptic terminal activity. Uptake by surrounding
glia can induce proinflammatory activity including ROS production, which is toxic to surrounding neurons. (9)
Impaired energy production and increased ROS production: Localisation of α-syn to mitochondrial membranes
may impair energy production or increase ROS formation. (10) Membrane pore formation: Ring-like oligomeric αsyn species may infiltrate cellular membranes forming pores within the membrane and altering ion permeability. Figure
compiled using information from [113, 114, 134, 138, 140-145].

cell transfer of toxic intermediates that alter synaptic protein expression and excitability [146].
Moreover, these extracellular species of α-syn can activate surrounding astrocytes and glia,
resulting in the production of ROS and proinflammatory cytokines, which in turn can be toxic to
surrounding neurons [145]. Finally, although inclusion bodies may sequester potentially harmful
aggregation intermediates, this process may also result in the depletion of proteins that become
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associated with the inclusions from the cytoplasm, leading to a loss in their biological activity
[142]. Together, these factors may lead to compromised cell viability (and cell death). However,
any one of these events (or combination thereof) may be sufficient given the delicate balance
required to maintain proteostasis.
3.2 Lewy bodies and Lewy neurites: α-synuclein is not alone
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Whilst α-syn is the main constituent of Lewy bodies and Lewy neurites, it is not the only protein
found in these insoluble inclusions: a range of other proteins has been identified including
synuclein-binding proteins, protein kinases, proteins implicated in the ubiquitin-proteasome system
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and proteins associated with the cellular stress response (e.g. molecular chaperones) [56].
Immunostaining of post-mortem brain tissue from PD patients indicates that Hsp90, Hsp70, Hsp40
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and the sHsps are associated with Lewy bodies and Lewy neurites [118, 147, 148]. With regard to
the sHsps, diffuse Hsp27 was identified throughout Lewy bodies and Lewy neurites in the
substantia nigra [147, 149] and αB-c also colocalises with α-syn in Lewy bodies and Lewy neurites
[149-152]. In addition, post-translationally modified forms of αB-c are a major component of
oligodendral cytoplasmic inclusions isolated from clinically confirmed cases of multiple system
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atrophy [59]. It remains to be established whether these chaperones associate with these protein
inclusions before or after they form in the cell. In any case, it appears that although these chaperone
proteins are available to inhibit α-syn aggregation in cells, under certain circumstances they are
unable to prevent its deposition and instead become part of the inclusions that are the hallmarks of
the α-synucleinopathies.
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4.

Small heat-shock proteins as molecular chaperones

There are ten human sHsps (HSPB1 – HSPB10), and of these the most well characterised are
Hsp27, αA-crystallin (αA-c), αB-c and Hsp20 (HSPB1, HSPB4, HSPB5 and HSPB6 respectively)
[153, 154]. Whilst sHsps are often described as ‘holdase’ chaperones, this term does not fully
describe their chaperone activity [155] and not all sHsps have been shown to be capable of
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suppressing target protein aggregation (e.g. HSPB9 and HSPB10). Structural aspects of sHsps have
been considered in detail elsewhere [156-159] and therefore the salient features are only
summarised here. The sHsps are defined by their relatively small (compared to other Hsps)
monomeric masses (12 – 43 kDa), and the presence of a conserved central region referred to as the
α-crystallin domain. The α-crystallin domain is ~90 residues in length and contains up to nine anti-
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parallel β-strands organised into β-sheets in an immunoglobulin-like fold [160, 161]. It is flanked
by N- and C-terminal regions of variable length and sequence that predominantly lack structure
[162]. In mammalian sHsps, the extreme C-terminus is a short, mobile and flexible extension which
is typically polar in nature and contributes to stabilisation of the protein (and complexes it forms
18

with target proteins) during chaperone action [163, 164]. The N-terminal region contains regions of
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significant hydrophobicity and has been suggested to mediate the interaction between the chaperone
and its target protein [165-168], although recent work demonstrates that the N-terminal region is not
essential for chaperone action function [169-171]. The formation of oligomeric assemblies is
another defining feature of the sHsps. Whilst in some species sHsps form well-defined homogenous
multimers (e.g. wheat Hsp16.9), many mammalian sHsps members (e.g. Hsp27, αB-c and αA-c)
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form large polydisperse oligomers which undergo rapid subunit exchange [169, 172-178]. The
popular model of sHsp chaperone action is that dissociated species (predominantly depicted as
dimers) are the most chaperone-active form; the rationale being that these species have a higher
degree of exposed hydrophobicity compared to the larger oligomeric forms, thereby facilitating
their interaction with partially folded target proteins that expose significant hydrophobicity to
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solution [173, 179]. In this model, the rate of subunit exchange of sHsps, which is highly dependent
on solution conditions (e.g. temperature) but independent of sHsp concentration [178, 180], dictates
how fast chaperone active subunits can be liberated from large oligomers, in order to interact with
and prevent the aggregation of target proteins. Our previous work has shown that αB-c is most
effective (on a mole: mole basis) at preventing the aggregation of slowly aggregating target proteins
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compared to those aggregating more quickly [10, 181], presumably because of the requirement for
active subunits to dissociate from larger oligomers as part of the chaperone action of sHsps. Thus,
when protein aggregation occurs very fast it may exceed the rate at which active sHsp subunits can
dissociate, therefore leading to a decrease in the chaperone efficacy of the sHsp.
4.1 Expression of sHsps in the brain
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Of the ten identified human sHsps, some are ubiquitously expressed (e.g. Hsp27 and αB-c), while
others are found only within specific tissues [182, 183]. For example, αA-crystallin is only present
at appreciable levels within the eye lens, where, together with αB-c, it forms α-crystallin, the
hetero-oligomeric lens protein which is responsible for maintaining lens transparency via its
chaperone action and ordered arrangement [184, 185]. Given the important role sHsps have in
19
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proteostasis, it is surprising that there has not been a systematic study of sHsp expression and
localisation in the human brain. In relation to neurodegenerative conditions such as the αsynucleinopathies, five sHsps are expressed within the central nervous system. Myotonic dystrophy
protein kinase binding protein (HSPB2) is expressed in smooth muscle of vessel walls of the brain
[186], and compartment-specific expression of Hsp20, Hsp22 (HSPB8), Hsp27 and αB-c has been
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demonstrated within other brain tissues of the mouse [187]. Hsp27 is expressed in motor and
sensory neurons in the brainstem and cranial nerve nuclei [188], and is also constitutively
expressed, along with αB-c, in glial cells [186].
Although there is some evidence for the neuroprotective capabilities of Hsp20 and Hsp22 [182],
Hsp27 and αB-c have attracted the most attention in relation to neurodegenerative disease. Both αB-
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c and Hsp27 expression are highly induced in response to neurological stress [151, 189]. Hsp27 and
αB-c are expressed in reactive astrocytes adjacent to senile plaques in both normal aged brains and
in neurodegenerative conditions, such as Alzheimer’s disease [186], and their expression is
increased in reactive astrocytes in the hippocampus of PD patients with dementia [190]. Moreover,
Hsp27 is one of the most strongly induced proteins across several brain regions in PD patients [191]
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and its levels are 2.5-fold higher in pathologically confirmed cases of Dementia with Lewy bodies
than age-matched controls. Chen and Brown [23] compared constitutive and inducible Hsp27
expression in several neuronal subtypes associated with neurodegenerative diseases, including PD
and amyotrophic lateral sclerosis (ALS). Constitutive Hsp27 expression was found within motor
neurons of the spinal cord (the degeneration of which is associated with ALS), but Hsp27 was not
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detected within dopaminergic neurons of the substantia nigra (the degeneration of which is
associated with PD). Chen and Brown speculated that one reason ALS is approximately 33 times
less frequent than PD is that motor neurons in the spinal cord are better equipped to manage
misfolded proteins than dopaminergic neurons due to the protection provided by the levels of Hsp27
[23]. Thus, the low basal expression of Hsp27 in dopaminergic neurons [23, 154] may facilitate the
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onset of α-syn aggregation in these cells. The increased expression of sHsps in the context of the α-
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synucleinopathies may be a consequence of the cellular stress conditions that accompanies the onset
and progression of these diseases.
4.2 The effects of small heat-shock proteins on α-synuclein aggregation
The presence of sHsps within Lewy bodies and their up-regulation in the surrounding neuronal
450

tissues associated with a number of α-synucleinopathies has led to an examination of how sHsps
interact with, and influence the aggregation of, α-syn. These findings, based on studies using in
vitro α-syn aggregation assays, and cell- and animal-based models of α-syn aggregation are
summarised in Table 1.

21

455

Table 1: A summary of studies that have investigated interactions between sHsps and α-syn. Key findings
regarding this interaction are categorised according to the method used.
Method used
In vitro
aggregation
assays and
atomic force
microscopy

α-Syn Isoform
WT
A53T
A30P
E46K

sHsp(s)
Hsp27
•
αB-c
Hsp20
•
Hsp22
HspB2B3

In vitro
aggregation
assays and
transmission
electron
microscopy
(TEM)
In vitro
aggregation
assays

WT
A53T
A30P

αB-c

WT

αB-c

In vitro assay,
TEM

A53T

•
•

•
•

αB-c

•
•

Key Findings
sHsps bind α-syn variants in a weak, transient but
specific manner
sHsps reduce the amount of fibrillar aggregation
resulting in fibrils that are shorter, and have a
clustered morphology.

Reference

[15]

αB-c inhibits α-syn fibril formation at
substoichiometric ratios.
The number of fibrils is significantly reduced and
amorphous-like aggregates are produced.

[11]

The ability of αB-c to suppress α-syn aggregation
increases with temperature.
αB-c inhibits further aggregation when
introduced during the elongation phase of fibril
growth.

[14]

The interaction of αB-c with α-syn monomers is
weak and transient. αB-c binds along the face and
ends of mature α-syn fibrils.
Fibril-bound αB-c inhibits further elongation.

[192]

In vitro
aggregation
assays

A53T

αB-c

•

αB-c significantly reduces the in vitro
aggregation of α-syn extracted and purified from
brain tissue of transgenic mice.

[193]

Cell-based
model

WT
A53T
A30P

Hsp27

•

Hsp27 expression protects stably transfected
ND7 α-syn-expressing cells from cell death
stimuli including serum withdrawal.

[194]

Cell-based
model

WT
A53T

Hsp27
αB-c

•

Both Hsp27 and αB-c co-localise with α-syn
inclusions in co-transfected H4 neuroglioma
cells.
Hsp27 reduces inclusion formation, although
both αB-c and Hsp27 reduce α-syn toxicity.
Hsp27 protects primary dopaminergic neurons
from α-syn toxicity.

[149]

•
•
Cell-based
model

WT

Hsp27

•

Hsp27 does not colocalise with α-syn in
inclusions

[147]

In vivo murine

A53T

Hsp25*
αB-c

•

Hsp25 levels are significantly up-regulated in
both the soluble and insoluble fractions of spinal
cord tissue of A53T α-syn over-expressing
transgenic mice.
αB-c levels are increased in the insoluble fraction
of spinal cord tissue from these transgenic mice.

[193]

αB-c reduces the ‘rough eye’ phenotype induced
by α-synuclein expression and aggregation in
Drosophila

[195]

•
In vivo
Drosophila

WT

αB-c

•

*Hsp25 is the murine ortholog of human Hsp27
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4.2.1

In vitro α-synuclein aggregation assays

sHsps interact with multiple species formed along the α-syn off-folding aggregation pathway
460

(Figure 4). Various sHsps, including Hsp27 and αB-c, bind monomeric α-syn in vitro, with a
dissociation rate constant (koff) in the range of 10-3s-1, as determined by surface plasmon resonance
measurements, suggesting a weak, transient interaction that nonetheless inhibits its aggregation
[15]. The ability of dyes such as thioflavin T (ThT) to bind to β-sheet structures (such as those
found in α-syn fibrils) has been used to monitor the aggregation kinetics of α-syn and provide a
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quantitative measure of fibril formation. Bruinsma et al. [15] assessed a panel of sHsps, including
Hsp27, Hsp20, Hsp22, HspB2B3 and αB-c, for their ability to inhibit α-syn aggregation using both
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Figure 4: sHsps interact with various species formed during the fibrillar aggregation of α-syn. Unfolded α-syn
aggregates through a nucleation-dependent mechanism, and the resultant fibrillar deposits may then be sequestered into
inclusion bodies. Fragmentation of mature fibrils can generate additional oligomeric nuclei, further perpetuating
aggregation. (1) The interaction of sHsps with monomeric aggregation-prone α-syn. The mechanism of this
interaction remains to be fully elucidated but may involve one or more of (i) weak transient interactions with α-syn
which prevent it from associating into oligomeric nuclei, (ii) the formation of a stable complex between α-syn and the
sHsps which, when cellular conditions permit, enable monomeric α-syn to be released, or (iii) α-syn being induced to
form amorphous aggregates rather than fibrils. (2) The interaction of sHsps with prefibrillar intermediates and
mature α-syn fibrils. sHsps can bind to oligomeric and fibrillar forms of α-syn with moderate (µM) affinity. In doing
so, they inhibit further fibril growth and may lead to tangling of the fibrils into larger ‘inclusion-like’ deposits. Solid
lines represent pathways that are well supported by the current literature, dotted lines represent proposed pathways in
which the details are yet to be fully resolved.
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in vitro ThT assays and atomic force microscopy. They reported that Hsp27 is the most efficacious
of these sHsps with regards to preventing fibril formation of WT α-syn and it does so by inhibiting
both the lag and elongation phases of aggregation [15]. This leads to an overall reduction in the
485

number and size of fibrils. Comparable effects were observed when Hsp27 was incubated with
E46K and A30P α-syn, however, the presence of Hsp27 increased the aggregation of A53T α-syn
compared to when no chaperone was present [15]. αB-crystallin also inhibits the aggregation of αsyn (and its disease-related mutant forms) in vitro and does so at sub-stoichiometric levels [11]. In
addition, the in vitro fibrillar aggregation of A53T α-syn isolated from brain tissue extracts of
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transgenic mice is significantly reduced by the presence of αB-c [193]. As with Hsp27, the addition
of αB-c not only increases the lag phase of α-syn aggregation, slowing the formation of prefibrillar
intermediates, but also inhibits the elongation phase, indicating that it acts to stabilize monomeric
and prefibrillar α-syn species [11, 14]. Notably, the efficiency with which αB-c inhibits α-syn fibril
formation correlates with the aggregation-propensity of the α-syn isoform [11, 15]. Thus, at a given
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molar ratio, αB-c is more effective at inhibiting the aggregation of WT α-syn (which aggregates the
slowest) and is less effective against A53T α-syn (which aggregates the fastest).
Most studies that have tested the in vitro chaperone action of the sHsps have involved addition of
the chaperone to α-syn before aggregation has commenced, and therefore focussed on the
interaction of the chaperone with species formed in the early stages of aggregation [11, 15, 196].
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However, in addition to interacting with monomeric and pre-fibrillar α-syn species, recent work has
shown that sHsps also bind to species formed further along the aggregation pathway including
mature fibrils [14, 192]. Thus, when introduced during the elongation phase of α-syn aggregation,
αB-c prevents further fibril growth by binding along the length of mature fibrils [14, 192]. Recent
work, using apolipoprotein C-II (apoC-II) as a model fibril-forming protein has shown that, by
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binding to fibrils, αB-c stabilises them and prevents their dilution-induced fragmentation [12].
Moreover, binding of αB-c to apoC-II fibrils also causes them to associate (tangle) into larger
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species reminiscent of protein inclusions [12]. Thus, it appears that by binding to fibrils, sHsps
inhibit their fragmentation and prevent secondary nucleation events, both of which contribute to
fibril toxicity [197]. Moreover, whilst the presence of sHsps within inclusions had been considered
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a by-product of their failed attempt to mitigate aggregation [196], their ability to stabilise mature αsyn fibrils provides another rationale for their localisation in these deposits. Finally, recently αB-c
was shown to also promote the dissociation of potentially toxic β2-microglobulin oligomers into
monomers, highlighting another role these chaperones may have in cells to protect them from α-syn
oligomer-induced toxicity [198].
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In summary, the interaction of sHsps with aggregation-prone α-syn is multi-faceted; it involves
binding to monomeric, oligomeric, prefibrillar and fibrillar forms of the protein in order to prevent
the toxicity associated with the aggregation process. However, as the chaperone action of sHsps is
dependent on the supply of dissociated (chaperone-active) species from larger oligomers, the
dynamic relationship between the rate at which α-syn aggregates and the rate of sHsp subunit
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exchange therefore appears to be an important factor with regards to whether or not sHsps can
prevent α-syn deposition in the context of the α-synucleinopathies.
4.2.2

Cell-based models of α-synuclein aggregation

Whilst it is clear that sHsps can interact with α-syn to inhibit its aggregation in vitro, it remains to
be conclusively established whether this occurs in the cellular environment. Most cell-based models
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of α-syn aggregation and associated toxicity are based on the exogenous application of aggregated
α-syn to cells in culture. The susceptibility of dopaminergic neurons to exogenous α-syn fibrils was
illustrated using preaggregated fragments of α-syn derived from a fibrillogenic region of the protein
encompassing residues 61-95 [199]. Administration of these fibrillar α-syn peptides to rat primary
mesenchephalic neurons results in a reduction of dopaminergic neurons and dopamine content
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[199]. Whilst exogenous application of α-syn fibrils may have relevance to cell-to-cell propagation
of aggregated α-syn [200-203], the intracellular aggregation of α-syn into Lewy body-like deposits
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most likely recapitulates the earliest events in disease and therefore is considered the most relevant
with regard to α-syn’s interaction with sHsps.
Overexpression of α-syn (via transfection or viral induction) has been examined in both primary
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and immortalised cell lines. Overexpression of both WT and A53T α-syn in primary
mesenchephalic neuronal cultures not only results in significant cell death, which is specific to
dopaminergic neurons and does not impact the viability of the other cells in the culture, but also
renders surviving dopaminergic neurons more susceptible to neurotoxic insults [204, 205].
Overexpression of WT, A53T and A30P α-syn in human neuroblastoma cells (SH-SY5Y) is not
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sufficient to cause extensive inclusion formation. However, co-treatment with various agents that
induce generation of ROS (e.g. rotenone, papaNONOate and FeCl2) results in the formation of
cytoplasmic protein inclusions in cells [206, 207]. The inclusions contain both α-syn and ubiquitin
and are therefore typical of Lewy bodies isolated from diseased tissue [206, 207]. Thus, it appears
that the presence of aggregation prone forms of α-syn per se is not sufficient to disrupt cellular
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proteostasis, however, a second insult that impacts on the proteostasis network can induce the
formation of these protein inclusions.
In studies in which α-syn is over-expressed, the extent of α-syn aggregation is dependent on both
the level and isoform of α-syn expressed:

A53T α-syn had an increased tendency to form

inclusions, consistent with its increased propensity to form fibrils in vitro and its genetic association
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with early onset PD [206]. McLean et al. [208] expressed an α-syn isoform which was C-terminally
tagged with enhanced green fluorescent protein (EGFP) in H4 neuroglioma cells and demonstrated
that overexpression of this protein results in cytoplasmic inclusions in ~5% of transfected cells.
Interestingly, cotransfection with synphilin-1, a protein which binds α-syn in vivo, increased the
percentage of cells containing inclusions to ~55% [208, 209]. Notably, although the α-syn was
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expressed with an EGFP fluorescent tag, inclusions were not fluorescent or reactive to anti-EGFP
antibodies [208]. This was due to C-terminal truncation of the EGFP attached to α-syn in these
cells, generating a non-fluorescent form of the protein which aggregated to form inclusions. Thus,
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these findings highlight the potential problems with tagging α-syn (and indeed other proteins) to
monitor its aggregation in cells. Alternative methods for studying full-length α-syn aggregation in
560

cells have also been developed. For example, using a tetra-cysteine tagged α-syn, that was either
microinjected or transfected into cells and detected by labelling with a fluorogenic biarsenical
compound, Bertoncinni et al. [210] demonstrated that the aggregation of α-syn into inclusions is
significantly increased (by up to 10%) by co-treating the cells with FeCl2 to induce oxidative stress.
More recently, α-syn aggregation in cells was modelled by the addition of a 16 amino acid peptide
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(termed CL1) to the C-terminus of α-syn, and this was used to demonstrate a correlation between
increasing numbers of α-syn aggregates in cells and a reduction in cell viability [211].
Much of what is known about the interaction between sHsps and α-syn in cells comes from cellbased models of α-syn like those described above. However, in general these cell models have only
been used qualitatively to assess the effects of sHsps on α-syn aggregation. One issue with these
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cell culture models of α-syn aggregation (which has hampered their use in quantitative studies) is
that often only a small proportion of the cells in culture develop inclusions when transfected [208].
This severely limits the types of biochemical analyses that can be undertaken with these models.
Despite this, there is some evidence for sHsps inhibiting α-syn aggregation in cells. For example,
using an α-syn overexpression system coupled with viral-mediated Hsp expression in ND7 cells,

575

Zourlidou et al. [194] reported a reduction in α-syn-induced cellular toxicity following
overexpression of Hsp27. Although this study focused on the inherent susceptibility of α-synexpressing cells to external cell death stimuli, such as serum removal, without directly considering
α-syn aggregation, it was concluded that Hsp27 is neuroprotective. Outeiro et al. [149] used
overexpression of the truncated EGFP-tagged WT α-syn in H4 cells (a model discussed above) to
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examine the effect of sHsps on α-syn aggregate formation and reported that cotransfection with
Hsp27 significantly reduced the percentage of cells containing α-syn inclusions. Both Hsp27 and
αB-c reduced the inherent toxicity of α-syn expression to levels similar to that seen when Hsp70 is
expressed in these cells [149]. The same effect was reproduced when A53T α-syn was
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overexpressed in primary midbrain cultures [149, 212]. Furthermore, a reduction in the endogenous
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levels of Hsp27 by siRNA resulted in a concentration-dependent increase in α-syn toxicity in the
transfected H4 model [149].
Apart from their ability to inhibit aggregation, sHsps may protect cells from the toxicity associated
with α-syn aggregation in other ways. Both Hsp27 and αB-crystallin increase the resistance of cells
to oxidative stress [213-215] and can inhibit apoptosis via a range of interactions with partner
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proteins involved in cell death pathways [216]. For instance, αB-crystallin inhibits autocatalytic
maturation of caspase-3 [217], and Hsp27 binds to caspase-3 and cytochrome-c released from
mitochondria causing inactivation of the caspase cascade [218, 219]. Caspase-independent
mechanisms have also been described, in which bound Hsp27 inhibits the ability of Daxx (death
domain-associated protein 6) to interact with Ask1 (apoptosis signal-regulated kinase 1) and Fas (a
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cell death regulator) [220], while αB-crystallin interacts with Bax and Bcl-2 to inhibit their
translocation to the mitochondria [221]. These interactions have all been shown to provide sHspmediated protection from apoptosis in cells. Thus, sHsps may protect cells from the cytotoxic
effects of α-syn aggregation via multiple mechanisms, not just by affecting its aggregation state.
Together, these cell culture studies have provided promising glimpses of the role (and therapeutic
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potential) of sHsps in preventing toxicity associated with α-syn aggregation in cells. However, more
robust and reliable cell culture models of α-syn aggregation are required so that the precise impact
of sHsps on α-syn aggregation and its associated toxicity can be unequivocally determined.
4.2.3

Animal-based models of α-synuclein aggregation

Surprisingly little work has been conducted into the impact of sHsps on α-syn aggregation and its
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associated toxicity using animal models. Various transgenic mouse models have been developed to
study the α-synucleinopathies (extensive reviews of this work are found in [222-224]). An example
of one such model is that developed by Lee and colleagues [225], in which the transgene is
introduced via embryonic pronuclear injection resulting in overexpression of human α-syn in glia
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and the neurons of the substantia nigra pars compacta. This model is characterised by pathological
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accumulation of α-syn in neuronal cell bodies and neurites in regions of the brain and spinal cord, in
parallel with ubiquitin deposition, reminiscent of the proteinaceous inclusions characteristic of the
α-synucleinopathies [225]. Using this model, immunohistochemical analysis of tissues from
symptomatic transgenic A53T α-syn mice demonstrated that the expression of αB-c and Hsp25 (the
murine ortholog of human Hsp27) increases in reactive astroglia and oligodendrocytes within
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affected regions of the central nervous system [193].
Transgenic α-syn models have also been developed in rats, Drosophila melanogaster and
Caenorhabditis elegans, as well as alternative models in which preaggregated α-syn protein or
fragments are injected directly into the substantia nigra [195, 199, 226-231]. These models have
been used as experimental tools to study the toxicity associated with α-synuclein aggregation.
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However, the impact sHsps have on α-syn aggregation in these models is yet to be explored. Tue et
al. [195] did demonstrate a reduction in the rough-eye phenotype of α-syn transgenic Drosophila in
the presence of αB-c, however the inhibition of α-syn aggregation was not directly examined.
Disease-relevant models such as these provide valuable tools to further examine the role (and
therapeutic potential) of sHsps in preventing α-syn aggregation in vivo and also may shed further
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light on the manner by which the cellular defences against protein aggregation are overwhelmed in
the α-synucleinopathies.
5.

Conclusions

The aggregation of α-syn into protein inclusions (Lewy bodies and Lewy neuritis) underlies the
onset and progression of the α-synucleinopathies and represents a failure of the proteostasis network
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in maintaining the protein in a biologically active, non-toxic form. Key components of the
proteostasis network are molecular chaperones and the sHsps are the cell’s first line of defence
against protein aggregation. We need to better understand why sHsps fail to prevent α-syn
aggregation in the context of the α-synucleinopathies. One of the main factors appears to be that the
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relatively low basal levels of αB-c and Hsp27 in dopaminergic neurons of the substantia nigra
635

makes them more susceptible to protein aggregation. If this is the case, then boosting their
expression may be a target for therapeutic intervention.
Whilst it has been generally considered that the role of sHsps in the chaperone network is to
stabilise partially folded intermediate states of protein to prevent their aggregation, recent work has
demonstrated that their mechanism of action is much more multi-faceted. In relation to α-syn
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aggregation, sHsps interact with multiple species formed during the aggregation process, from
monomeric partially folded intermediate states through to the mature fibrils themselves. The
biological relevance of these interactions must now be further examined using more sophisticated
disease-relevant cell and animal models of the α-synucleinopathies.
In addition, whilst many studies have primarily considered the ability of the sHsps to inhibit or
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prevent α-syn aggregation in vitro, the limited number of cellular and in vivo studies performed to
date indicate that they may not significantly alter the number of inclusions formed in cells. Instead,
sHsps may afford protection against the toxicity associated with α-syn aggregation via their impacts
on other cellular pathways, such as by inhibiting ROS formation or apoptosis. The common theme
in all this work is that sHsps act, through their chaperone activity, to stabilise proteins and prevent
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their improper interactions in cells. In doing so, they maintain cell viability and therefore are key
components of the proteostasis network. In the α-synucleinopathies, targeting their chaperone
activity in the context of the α-synucleinopathies may open up new therapeutic avenues to treat
these currently intractable and debilitating diseases.
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